Functions and Inhibition of Galectin-7, an Emerging Target in Cellular Pathophysiology

Sewgobind, Nishant V.; Albers, Sanne; Pieters, Roland J.

doi:10.3390/biom11111720

Cited by 13 publications

(8 citation statements)

References 117 publications

(157 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Galectins are a subfamily of proteins involved in regulating numerous biological processes, including inflammation and blood vessel remodeling, both of which occur in scleroderma (also known as systemic sclerosis, SSc). Four galectins -galectin-1, galectin-3, galectin-7, and galectin-9 − have been investigated in scleroderma [22,23,24].…”

Section: Resultsmentioning

confidence: 99%

Novel biomarkers in systemic sclerosis

Agachi¹,

Groppa²,

Rotaru³

et al. 2022

MJHS

View full text Add to dashboard Cite

Introduction. Due to the heterogeneous nature of systemic sclerosis, it is difficult to predict disease progression and complications. Despite the discovery of novel autoantibodies associated with systemic sclerosis (SSc), there is an unmet need for biomarkers for diagnosis, disease progression, and response to treatment. Materials and methods. An analytical, qualitative study was performed with a narrative review of literature in the form of a synthesis article. Relevant primary sources published in 2020-2022 were identified and selected, using data extraction and analysis. Results. Anti-citrullinated protein/peptide antibody could be useful in identifying patients with a more prominent joint disease. Of most interest, the anti-carbamylated protein antibodies (anti-CarP) could be a relevant biomarker related to fibrotic skin and lung disease. Positive anti-RNA (Ribonucleic acid) polymerase III antibody and antinuclear antibodies (ANA) negativity were significantly associated with GAVE (gastral antral vascular ectasia). Autoantibodies against telomeres may help identify systemic sclerosis with lung disease. Osteopontin links myeloid activation and disease progression in systemic sclerosis. CTRP (C1q tumor necrosis factor-related proteins) 9 protein levels may be biomarker of lung disease severity. CD (cluster differentiation) 21-low B cells are linked to vascular damage. L-tyrosine, L-tryptophan, and 1-methyl-adenosine distinguished healthy controls from SSc patients. L-leucine, L-isoleucine, xanthosine, and adenosine monophosphate differentiated between progressing and stable SSc-ILD. CECs (circulating endothelial cells) are a direct indicator of systemic vascular damage. Levels of the protein, galectin-3, are associated with heart involvement in people with systemic sclerosis. Low levels of the galectin-10 protein (Gal-10) in scleroderma patients associate with inflammation and vascular changes in the lungs, leading to pulmonary arterial hypertension (PAH). High levels of the CD146 protein may be a potential biomarker in identifying people with systemic sclerosis. Blood levels of the protein endocan increased in scleroderma patients who are at risk for pulmonary arterial hypertension. FLCs (free light chain) could be employed as useful potential biomarker of early diagnosis and to follow disease activity. Conclusions. Novel discovered biomarkers could predict disease development, activity, and severity of diverse organ involvement, predict risk of complications of systemic sclerosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Novel biomarkers in systemic sclerosis

Agachi¹,

Groppa²,

Rotaru³

et al. 2022

MJHS

View full text Add to dashboard Cite

show abstract

“…Galectin-7 was described as an epithelial differentiation marker in different organs (110). High expression levels of galectin-7 were found in aggressive subtypes of breast cancer, frequently with a basal-like phenotype and estrogen receptor-negative tumors (111).…”

Section: Galectin-7mentioning

confidence: 99%

Galectin functions in cancer-associated inflammation and thrombosis

Kruk

Braun²,

Cosset³

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Galectins are carbohydrate-binding proteins that regulate many cellular functions including proliferation, adhesion, migration, and phagocytosis. Increasing experimental and clinical evidence indicates that galectins influence many steps of cancer development by inducing the recruitment of immune cells to the inflammatory sites and modulating the effector function of neutrophils, monocytes, and lymphocytes. Recent studies described that different isoforms of galectins can induce platelet adhesion, aggregation, and granule release through the interaction with platelet-specific glycoproteins and integrins. Patients with cancer and/or deep-venous thrombosis have increased levels of galectins in the vasculature, suggesting that these proteins could be important contributors to cancer-associated inflammation and thrombosis. In this review, we summarize the pathological role of galectins in inflammatory and thrombotic events, influencing tumor progression and metastasis. We also discuss the potential of anti-cancer therapies targeting galectins in the pathological context of cancer-associated inflammation and thrombosis.

show abstract

“…Intracellular galectin-7 promotes cell apoptosis by increasing the activity of caspase-3 ( 129 ), accelerating the release of cytochrome C, and enhancing the activity of amino-terminal kinases that play important roles in maintaining epidermal homeostasis ( 129 , 130 ). Galectin-7 is also involved in cell adhesion and migration and functions in wound healing, cancer progression, embryonic development, allergic inflammation, autoimmune diseases, and transplant rejection ( 131 ). Galectin-7 increases the expression levels of matrix metalloproteinase (MMP)-9, which has vital roles in tumorigenesis, metastasis, migration, and invasion via regulating extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 mitogen activated protein kinase signaling pathways ( 132 , 133 ).…”

Section: Galectin-7mentioning

confidence: 99%

Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?

Shi

Tang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

The galectin family of proteins has high affinity with β-galactoside-containing glycans. These proteins participate in cell growth and differentiation, cell adhesion, cell signal transduction, cell apoptosis, and other cellular activities. In recent years, a large number of studies have described the expression and correlation of galectins in different tumors. Each member of the family plays a vital role in tumor growth, progression, angiogenesis, adhesion, and tumor immune escape. Studies on the roles of galectins in lymphoma have mainly involved galectin-1, -3, -7, and -9. The results suggest that galectins may become novel targets for precise tumor treatment. This article reviews current research progress regarding galectins in lymphoma and provides new ideas for exploring them as novel targets for treating lymphoma and other important medical issues.

show abstract

Functions and Inhibition of Galectin-7, an Emerging Target in Cellular Pathophysiology

Cited by 13 publications

References 117 publications

Novel biomarkers in systemic sclerosis

Novel biomarkers in systemic sclerosis

Galectin functions in cancer-associated inflammation and thrombosis

Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?

Contact Info

Product

Resources

About